BOSTON, April 9, 2025 -- Solu Therapeutics, a biotechnology company pioneering therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today announced the successful completion of a $41 million Series...
AutoGenomics announces the launch of a novel test for B-RAF mutations
News | 02. 24. 2010
AutoGenomics, a leader in providing automated, molecular testing solutions announced today that it has launched an expanded test panel to detect 17 B-RAF mutations for research use to enhance the understanding of B-RAF mutations.
